Legacy unique identifier: P00478

This statistic shows the overall mortality rate from infectious diseases in China from 2015 to 2021. In 2021, approximately 1.57 out of 100,000 people in China died due to communicable diseases, an increase from the year prior mainly due to the high mortality rate of the coronavirus infection.

Since 2008, HIV/AIDS remains the most fatal infectious disease in China. In 2021, almost 14 out of one million people in China died from AIDS. Tuberculosis stood at the second place, while rabies ranked the fourth.

Who are the high risk groups?

The HIV/AIDS epidemic has become a growing concern for the major population in China. A majority of new infections were the result from sexual transmission. Although the prevalence rate has been relatively low, the trend of new diagnoses in people aged from 15 to 24 years has been alarming, with gay men disproportionately represented.

Children under the age of 14 are the most vulnerable group to contract common infectious diseases like influenza and HFMD. The Chinese government has thus introduced healthcare initiatives dedicated to vaccinating children up to the age of 14 under the Extended Program for Immunization (EPI). The efforts have been fruitful with significant improvement in the healthcare status of children under the age of five in the country.

How is disease controlled in China?

The world’s most populous nation has made considerable efforts in tracking and preventing the spread of infectious diseases. Alongside geographical and demographic challenges, the mortality rate of infectious diseases has seen a slight increase over the recent years. Seasonal diseases, especially Influenza and mumps, are easily widespread and have pressed the demand for efficient disease prevention and control. In response, the Chinese government has ramped up the supply of influenza vaccines and HPV vaccines.

Tuberculosis is one of the deadliest communicable diseases worldwide, causing around 1.4 million deaths per year. Communicable diseases, also known as infectious diseases, are spread from person to person either directly or indirectly, such as through an insect bite or ingesting contaminated food or water. Some of the deadliest communicable diseases include HIV/AIDS, malaria, hepatitis C, cholera, and measles. Tuberculosis Tuberculosis is an infectious disease that affects the lungs. Tuberculosis disproportionately impacts the poorer, less developed countries of the world, such as in Africa and Southeast Asia. India reports the highest number of deaths from tuberculosis worldwide. HIV/AIDS Although deaths from HIV/AIDS have decreased over the last few decades, there were still around 630,000 AIDS-related deaths in 2023. Like many other communicable diseases, HIV/AIDS impacts developing regions more than the developed world. By far, the highest number of AIDS deaths come from Africa and Asia Pacific. Advancements in HIV treatment now allow those infected to live long and relatively normal lives, but access to treatment varies greatly.

Legacy unique identifier: P00491

It is estimated that around nine percent of the population in the United States has been diagnosed with an infectious disease. Infectious diseases are caused by bacteria, viruses and other organisms and can be spread from person to person, through insect or animal bites, or through contaminated food or water. Some of the most common infectious diseases include HIV/AIDS, influenza, malaria, tuberculosis and hepatitis.

HIV/AIDS

HIV/AIDS is one of the most well-known infectious diseases worldwide. There are currently almost 38 million people worldwide living with HIV and it is responsible for just under a million deaths per year. HIV treatment has improved dramatically over the last few decades but access to treatment varies. The poorer regions of the world still suffer disproportionately from HIV with the majority of those infected living in Africa.

Tuberculosis

Like HIV/AIDS, tuberculosis also impacts the poorer regions of the world more than developed nations. Tuberculosis impacts the lungs of those infected and is currently the tenth leading cause of death worldwide. The countries with the highest incidence rates of tuberculosis include India, China, Indonesia, and the Philippines. In India alone tuberculosis was responsible for around 440,000 deaths in 2018.

Among infectious diseases that were recorded in Japan, the highest number of deaths was caused by the coronavirus disease (COVID-19), which amounted to approximately 47.6 thousand deaths in 2022. The number of deaths from infectious enterogastritis followed with around two thousand cases.  Seasonal influenza in Japan  The influenza season in Japan typically begins in November or December and reaches its peak in the first two months of the following year. The number of deaths caused by seasonal flu in Japan has been increasing in recent years. Since 2010, more than 25 million influenza vaccine units were supplied in the country annually. Citizens aged 60 years and over are eligible to receive free periodic influenza vaccines from their municipality. In recent years, more than 20 million elderly have received such a free vaccination yearly.  Receding flu infections during COVID-19 During the COVID-19 pandemic in recent years, a partial decrease in monthly flu patients was observed in Japan. This development has by some been attributed to a phenomenon called viral interference, making people less susceptible to influenza viruses in areas where the coronavirus is predominant. In case of an infection with the novel virus, infected cells secrete so-called interferon proteins which block other viruses. Moreover, nationwide preventive measures such as face masks, home office implementation, and regulations of gastronomy opening hours have shown to have a positive influence on reducing infection numbers of diseases like influenza.

Years of life lost due to mortality from infectious and parasitic disease (ICD-10 A00-B99). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00458

The age-specific mortality rate of other and unspecified infectious and parasitic diseases and their sequelae at all ages in Canada increased by 0.8 deaths (+23.53 percent) in 2023. Therefore, the age-specific mortality rate in Canada reached a peak in 2023 with 4.2 deaths.

This table presents a wide variety of historical data in the field of health, lifestyle and health care. Figures on births and mortality, causes of death and the occurrence of certain infectious diseases are available from 1900, other series from later dates. In addition to self-perceived health, the table contains figures on infectious diseases, hospitalisations per diagnosis, life expectancy, lifestyle factors such as smoking, alcohol consumption and obesity, and causes of death. The table also gives information on several aspects of health care, such as the number of practising professionals, the number of available hospital beds, nursing day averages and the expenditures on care. Many subjects are also covered in more detail by data in other tables, although sometimes with a shorter history. Data on notifiable infectious diseases and HIV/AIDS are not included in other tables.

Data available from: 1900

Status of the figures:

2024: The available figures are definite. 2023: Most available figures are definite. Figures are provisional for: - occurrence of infectious diseases; - expenditures on health and welfare; - perinatal and infant mortality. 2022: Most available figures are definite. Figures are provisional for: - occurrence of infectious diseases; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - expenditures on health and welfare. 2021: Most available figures are definite. Figures are provisional for: - occurrence of infectious diseases; - expenditures on health and welfare. 2020 and earlier: Most available figures are definite. Due to 'dynamic' registrations, figures for notifiable infectious diseases, HIV, AIDS remain provisional.

Changes as of 18 december 2024: - Due to a revision of the statistics Health and welfare expenditure 2021, figures for expenditure on health and welfare have been replaced from 2021 onwards. - Revised figures on the volume index of healthcare costs are not yet available, these figures have been deleted from 2021 onwards.

The most recent available figures have been added for: - live born children, deaths; - occurrence of infectious diseases; - number of hospital beds; - expenditures on health and welfare; - perinatal and infant mortality; - healthy life expectancy; - causes of death.

When will new figures be published? July 2025.

BackgroundThe prospect of eliminating onchocerciasis from Africa by mass treatment with ivermectin has been rejuvenated following recent successes in foci in Mali, Nigeria and Senegal. Elimination prospects depend strongly on local transmission conditions and therefore on pre-control infection levels. Pre-control infection levels in Africa have been mapped largely by means of nodule palpation of adult males, a relatively crude method for detecting infection. We investigated how informative pre-control nodule prevalence data are for estimating the pre-control prevalence of microfilariae (mf) in the skin and discuss implications for assessing elimination prospects.Methods and FindingsWe analyzed published data on pre-control nodule prevalence in males aged ≥20 years and mf prevalence in the population aged ≥5 years from 148 African villages. A meta-analysis was performed by means of Bayesian hierarchical multivariate logistic regression, accounting for measurement error in mf and nodule prevalence, bioclimatic zones, and other geographical variation. There was a strong positive correlation between nodule prevalence in adult males and mf prevalence in the general population. In the forest-savanna mosaic area, the pattern in nodule and mf prevalence differed significantly from that in the savanna or forest areas.SignificanceWe provide a tool to convert pre-control nodule prevalence in adult males to mf prevalence in the general population, allowing historical data to be interpreted in terms of elimination prospects and disease burden of onchocerciasis. Furthermore, we identified significant geographical variation in mf prevalence and nodule prevalence patterns warranting further investigation of geographical differences in transmission patterns of onchocerciasis.

These data contain case counts and rates for selected communicable diseases—listed in the data dictionary—that met the surveillance case definition for that disease and was reported for California residents, by disease, county, year, and sex. The data represent cases with an estimated illness onset date from 2001 through the last year indicated from California Confidential Morbidity Reports and/or Laboratory Reports. Data captured represent reportable case counts as of the date indicated in the “Temporal Coverage” section below, so the data presented may differ from previous publications due to delays inherent to case reporting, laboratory reporting, and epidemiologic investigation.

The projected number of patients suffering from communicable diseases is expected to reach about 60 million by 2024. In that year, the population growth will decline slightly but there will be an increase of the elderly over 65 years old. Alongside with the population structure, the prevalence of diseases changes proportionally.

BackgroundEstimating the burden of healthcare-associated infections (HAIs) compared to other communicable diseases is an ongoing challenge given the need for good quality data on the incidence of these infections and the involved comorbidities. Based on the methodology of the Burden of Communicable Diseases in Europe (BCoDE) project and 2011–2012 data from the European Centre for Disease Prevention and Control (ECDC) point prevalence survey (PPS) of HAIs and antimicrobial use in European acute care hospitals, we estimated the burden of six common HAIs.Methods and FindingsThe included HAIs were healthcare-associated pneumonia (HAP), healthcare-associated urinary tract infection (HA UTI), surgical site infection (SSI), healthcare-associated Clostridium difficile infection (HA CDI), healthcare-associated neonatal sepsis, and healthcare-associated primary bloodstream infection (HA primary BSI). The burden of these HAIs was measured in disability-adjusted life years (DALYs). Evidence relating to the disease progression pathway of each type of HAI was collected through systematic literature reviews, in order to estimate the risks attributable to HAIs. For each of the six HAIs, gender and age group prevalence from the ECDC PPS was converted into incidence rates by applying the Rhame and Sudderth formula. We adjusted for reduced life expectancy within the hospital population using three severity groups based on McCabe score data from the ECDC PPS. We estimated that 2,609,911 new cases of HAI occur every year in the European Union and European Economic Area (EU/EEA). The cumulative burden of the six HAIs was estimated at 501 DALYs per 100,000 general population each year in EU/EEA. HAP and HA primary BSI were associated with the highest burden and represented more than 60% of the total burden, with 169 and 145 DALYs per 100,000 total population, respectively. HA UTI, SSI, HA CDI, and HA primary BSI ranked as the third to sixth syndromes in terms of burden of disease. HAP and HA primary BSI were associated with the highest burden because of their high severity. The cumulative burden of the six HAIs was higher than the total burden of all other 32 communicable diseases included in the BCoDE 2009–2013 study. The main limitations of the study are the variability in the parameter estimates, in particular the disease models’ case fatalities, and the use of the Rhame and Sudderth formula for estimating incident number of cases from prevalence data.ConclusionsWe estimated the EU/EEA burden of HAIs in DALYs in 2011–2012 using a transparent and evidence-based approach that allows for combining estimates of morbidity and of mortality in order to compare with other diseases and to inform a comprehensive ranking suitable for prioritization. Our results highlight the high burden of HAIs and the need for increased efforts for their prevention and control. Furthermore, our model should allow for estimations of the potential benefit of preventive measures on the burden of HAIs in the EU/EEA.

Qatar QA: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data was reported at 5.200 % in 2016. This records a decrease from the previous number of 5.300 % for 2015. Qatar QA: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data is updated yearly, averaging 5.400 % from Dec 2000 (Median) to 2016, with 4 observations. The data reached an all-time high of 8.800 % in 2000 and a record low of 5.200 % in 2016. Qatar QA: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Qatar – Table QA.World Bank.WDI: Health Statistics. Cause of death refers to the share of all deaths for all ages by underlying causes. Communicable diseases and maternal, prenatal and nutrition conditions include infectious and parasitic diseases, respiratory infections, and nutritional deficiencies such as underweight and stunting.; ; Derived based on the data from WHO's Global Health Estimates.; Weighted average;

The complexity of COVID-19 and variations in control measures and containment efforts in different countries have caused difficulties in the prediction and modeling of the COVID-19 pandemic. We attempted to predict the scale of the latter half of the pandemic based on real data using the ratio between the early and latter halves from countries where the pandemic is largely over. We collected daily pandemic data from China, South Korea, and Switzerland and subtracted the ratio of pandemic days before and after the disease apex day of COVID-19. We obtained the ratio of pandemic data and created multiple regression models for the relationship between before and after the apex day. We then tested our models using data from the first wave of the disease from 14 countries in Europe and the US. We then tested the models using data from these countries from the entire pandemic up to March 30, 2021. Results indicate that the actual number of cases from these countries during the first wave mostly fall in the predicted ranges of liniar regression, excepting Spain and Russia. Similarly, the actual deaths in these countries mostly fall into the range of predicted data. Using the accumulated data up to the day of apex and total accumulated data up to March 30, 2021, the data of case numbers in these countries are falling into the range of predicted data, except for data from Brazil. The actual number of deaths in all the countries are at or below the predicted data. In conclusion, a linear regression model built with real data from countries or regions from early pandemics can predict pandemic scales of the countries where the pandemics occur late. Such a prediction with a high degree of accuracy provides valuable information for governments and the public.

The register of infectious diseases is a national database established on the basis of the Prevention and Control of Infectious Diseases Act. The register is kept for the purpose of registering infectious disease cases, conducting epidemiological studies of infectious diseases, clarifying the trends in the spread of infectious diseases, preventing infectious diseases, controlling and organizing health services, developing health policy, analyzing the morbidity, prevalence and mortality of infectious diseases, evaluating diagnostics and treatment, and conducting statistics and scientific research.

NNDSS - TABLE 1R. Hepatitis C, perinatal infection to Influenza-associated pediatric mortality - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notes: • These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance. Footnotes: *Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). § Please refer to the CDC WONDER publication for weekly updates to the footnote for this condition. U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

Data and code to reproduce the analyses in:Farrell, M.J., & Davies, T.J. (2019) "Disease mortality in domesticated animals is predicted by host evolutionary relationships"Detailed information on R scripts and and metadata is included in the enclosed file "Farrell_Davies_Metadata.pdf"

In 2019, the leading causes of death globally included ischemic heart disease, stroke and chronic obstructive pulmonary disease (COPD). There were 8.89 million deaths from ischemic heart disease at that time and about 6.19 million deaths caused by stroke. In recent history, increases in life expectancy, increases in population and better standards of living have changed the leading causes of death over time.

Non-Communicable Disease Deaths

The number of deaths due to non-communicable diseases has remained relatively stable in recent years. A large majority of non-communicable or chronic disease deaths globally were caused by cardiovascular diseases, followed by cancer. Various lifestyle choices cause or exacerbate many of these chronic diseases. Drinking, smoking and lack of exercise can contribute to higher rates of non-communicable diseases and early death. A 2018 report indicated that the relative risk of death before the age of 65 was 24 times greater among those that smoked and never quit.

Infectious Disease Deaths

Trends indicate that the number of deaths due to infectious diseases have decreased in recent years. However, infectious diseases still disproportionately impact low- and middle-income countries. In 2016, tuberculosis, malaria and HIV/AIDS were still among the leading causes of death in low-income countries. However, the leading causes of death in upper income countries are almost exclusively non-communicable, chronic conditions.